Background. Clostridium difficile infection (CDI) is common in the elderly due to decreased immunity and frequent antibiotic and healthcare exposure. We investigated antibiotic use in hospitalized long term care facility (LTCF) residents that developed CDI to identify potential stewardship targets.
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Methods. CDI cases were identified by the CDC's Emerging Infections Program active population surveillance. Incident cases were LTCF residents with a positive stool test within 30 days post-hospitalization and more than 8 weeks from a previous positive. Antibiotic use and readmission data were abstracted from hospital medical records.
Results. Records of 130 Monroe County, NY residents discharged from 4 acute care hospitals to 33 LTCFs were reviewed. Thirty-one (24%) patients were readmitted to the hospital within 2 days before or 7 days after CDI. Thirty-two (25%), 104 (80%), and 51 (39%) patients received antibiotics pre-and during hospitalization and at hospital discharge, respectively (table). Fluoroquinolones, first and third generation cephalosporins and extended-spectrum penicillin combinations were the most common. Common indications included lower respiratory tract infections (LRTI) and urinary tract infections (UTI); however review of the UTI cases showed that 60% of 25 non-catheterized patients did not meet the McGeer UTI criteria. Conclusion. LTCF residents developing CDI after acute care hospitalization had frequent antibiotic exposure prior to CDI diagnosis to treat presumed UTI and LRTI. These antibiotics were administered before, during and at discharge from hospitalization. This highlights the need for stewardship activities that target antibiotic usage across the continuum of care, particularly at care transition.
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